Early Zalunfiban Injection Effective for Major Heart Attack:
In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced the risk of adverse 30-day clinical outcomes without increasing severe bleeding. In an international, double-blind, placebo-controlled trial of 2,467 patients randomly assigned to receive zalunfiban (0.11 mg/kg or 0.13 mg/kg) […]